Gilead’s Lenacapavir On The Move Again As FDA Lifts Clinical Hold
Executive Summary
The long-acting HIV drug’s greatest potential is for pre-exposure prophylaxis, where it would compete against ViiV’s long-acting injectable Apretude.
You may also be interested in...
Gilead Gets Lenacapavir To EU Approval For HIV Salvage Therapy, Awaits FDA’s Call
A first-in-class capsid inhibitor, lenacapavir is a linchpin of Gilead’s long-term strategy in HIV treatment and prevention, but has faced regulatory setbacks in the US.
From Treatment To Prevention To A Cure: An Interview With Gilead’s HIV R&D Leaders
Gilead execs Jared Baeten and Tomas Cihlar talk to Scrip about how the company, still the leader in HIV, is working toward less-frequent dosing, providing PrEP for broader populations and maybe finding a cure for HIV infection.
Gilead Oncology Sales Take Off As Veklury’s Come Down To Earth
As expected, the COVID-19 drug’s sales fell significantly, though it remains in frequent use among hospitalized patients. Meanwhile, oncology drug sales broke the half billion-dollar mark.